⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CTOR News
Citius Oncology, Inc. Common Stock
Form 8-K
sec.gov
CTOR
Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell Lymphoma
prnewswire.com
CTXR
CTOR
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
prnewswire.com
CTXR
CTOR
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
prnewswire.com
CTXR
CTOR
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
prnewswire.com
CTXR
CTOR
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
prnewswire.com
ONCY
BCTX
GLSI
CTOR
KZIA
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Citius Oncology, Inc. (NASDQ: CTOR)
prnewswire.com
CTOR
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
prnewswire.com
CTXR
CTOR
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
prnewswire.com
CTOR
CTXR
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
prnewswire.com
CTOR
CTXR